Luo Jian-Quan, Wang Lu-Yan, He Fa-Zhong, Sun Ning-Ling, Tang Gen-Fu, Wen Jia-Gen, Luo Zhi-Ying, Liu Zhao-Qian, Zhou Hong-Hao, Chen Xiao-Ping, Zhang Wei
Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, Hunan 410078, PR China.
Pharmacogenomics. 2014 Feb;15(2):201-8. doi: 10.2217/pgs.13.173. Epub 2013 Sep 23.
The mineralocorticoid receptor (MR; also known as NR3C2) plays important roles in the modulation of blood pressure. The effect of NR3C2 polymorphisms on antihypertensive response to enalapril was investigated.
PATIENTS & METHODS: Two hundred and seventy nine essential hypertension patients treated with enalapril were genotyped for two NR3C2 tagSNPs, rs5522 and rs2070950, by Sequenom MassArray™ technology.
The reductions in diastolic blood pressure (DBP) were significantly greater in AA homozygotes compared with AG+GG genotype carriers for the rs5522 polymorphism (p = 0.009), and the reductions in DBP were greater in GG homozygotes compared with GC+CC genotype carriers for the rs2070950 polymorphism, with marginal significance (p = 0.065). Stepwise multiple regression analysis indicated that significant predictors of DBP reduction were baseline DBP (p < 0.001), waist:hip ratio (p = 0.001) and rs5522 genotype (p = 0.003).
NR3C2 rs5522 affects blood pressure response to enalapril treatment and may serve as a useful pharmacogenomic marker of antihypertensive response to enalapril in essential hypertension patients.
盐皮质激素受体（MR；也称为NR3C2）在血压调节中起重要作用。研究了NR3C2基因多态性对依那普利降压反应的影响。
采用Sequenom MassArray™技术对279例接受依那普利治疗的原发性高血压患者进行两个NR3C2标签单核苷酸多态性（tagSNP），即rs5522和rs2070950的基因分型。
对于rs5522多态性，AA纯合子的舒张压（DBP）降低幅度显著大于AG + GG基因型携带者（p = 0.009）；对于rs2070950多态性，GG纯合子的DBP降低幅度大于GC + CC基因型携带者，具有边缘显著性（p = 0.065）。逐步多元回归分析表明，DBP降低的显著预测因素为基线DBP（p < 0.001）、腰臀比（p = 0.001）和rs5522基因型（p = 0.003）。
NR3C2 rs5522影响依那普利治疗的血压反应，可能是原发性高血压患者对依那普利降压反应的有用药物基因组学标志物。
